menu
    • menu

    Company profile for Theolytics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establi...
    Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Theolyticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Innovation Building Roosevelt Drive Oxford England OX3 7FZ
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.theolytics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Theolytics Doses First Patient in Phase 1 Ovarian Cancer Trial
    Theolytics Doses First Patient in Phase 1 Ovarian Cancer Trial

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282264/0/en/theolytics-announces-first-patient-dosed-in-the-octopod-ip-trial-a-us-phase-1-trial-with-theo-260-a-novel-oncolytic-immunotherapy-targeting-ovarian-cancer.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Theolytics Secures €8M Grant To Advance THEO-260 Phase 2 Study
    Theolytics Secures €8M Grant To Advance THEO-260 Phase 2 Study

    04 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-04/theolytics-awarded-8-million-in-horizon-europe-2025-grant-funding-to-advance-phase-2-study-of-theo-260-in-ovarian-cancer

    PHARMIWEB
    04 Mar 2026
    Share Share
    Theolytics Showcases THEO-260 In Ovarian Cancer Trial At ESMO
    Theolytics Showcases THEO-260 In Ovarian Cancer Trial At ESMO

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165321/0/en/Theolytics-to-Present-Ongoing-Phase-I-IIa-OCTOPOD-IV-Trial-of-THEO-260-in-Ovarian-Cancer-at-ESMO-2025.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share
    Theolytics Names Matilde Saggese, MD, Chief Medical Officer
    Theolytics Names Matilde Saggese, MD, Chief Medical Officer

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162239/0/en/Theolytics-Appoints-Experienced-Medical-Oncologist-Matilde-Saggese-MD-as-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Theolytics Appoints David Apelian MD, PhD, MBA as CEO
    Theolytics Appoints David Apelian MD, PhD, MBA as CEO

    17 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/17/2998000/0/en/Theolytics-Appoints-David-Apelian-MD-PhD-MBA-as-CEO.html

    GLOBENEWSWIRE
    17 Dec 2024
    Share Share
    Theolytics Doses 1st Patient in Ph I/IIa of THEO-260 in Cancer
    Theolytics Doses 1st Patient in Ph I/IIa of THEO-260 in Cancer

    19 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/19/2983294/0/en/Theolytics-Doses-First-Patient-in-Phase-I-IIa-Trial-of-THEO-260-in-Ovarian-Cancer.html

    GLOBENEWSWIRE
    19 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search